Clinical Report: Management of Metachronous Bilateral Breast Cancer

Overview

This case study presents a 37-year-old woman with metachronous bilateral breast cancer exhibiting discordant receptor profiles. The management involved neoadjuvant chemotherapy.

Background

Bilateral breast cancer is rare, comprising 2%–5% of breast cancer cases. The presence of triple-negative breast cancer (TNBC) alongside hormone-responsive tumors complicates treatment strategies due to their distinct biological behaviors and prognostic implications.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• The patient had a left-sided tumor classified as PR-positive, ER-negative, and HER2-negative.
• The right-sided tumor was identified as triple-negative invasive carcinoma.
• Neoadjuvant chemotherapy was initiated using the adriamycin and cyclophosphamide regimen.
• Significant weight loss was noted in the patient during treatment.
• Multidisciplinary management is essential for addressing the complexities of treatment in bilateral breast cancer cases.

Clinical Implications

Neoadjuvant chemotherapy can facilitate tumor downstaging and inform surgical planning.

Conclusion

Metachronous bilateral breast cancer with differing receptor profiles presents significant management challenges.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- A case report of synchronous bilateral breast cancer with distinct histological subtypes and favorable long-term survival
2. The ASCO Post, 2022 -- Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors
3. The ASCO Post, 2020 -- High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
4. The ASCO Post, 2015 -- Complexities of Targeting HER2 in Estrogen Receptor–Positive Breast Cancers
5. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease - PMC
6. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer - PubMed
7. Evolution of synchronous female bilateral breast cancers and response to treatment | Nature Medicine
8. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease - PMC
9. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer - PubMed
10. Evolution of synchronous female bilateral breast cancers and response to treatment | Nature Medicine